drugset / Trial / NCT01453296

Pharmacokinetics and Pharacodynamics of GW642444 in Paedetric Subjects

NCT01453296

Phase 2 Completed 28 enrolled GlaxoSmithKline
RandomizedCrossoverTriple-blindTreatment

Summary

This study will investigate the effect of dosing paedeatric asthmatic subjects with GW642444, an orally inhaled long-acting agonist of the β2-adrenoceptor.

Timeline

Start
2010-08
Primary completion
2011-04
Completion
2011-04

Drugs

EvaluationDrugModalityDoseRoute
Comparator Vilanterol Other / unclassified 25 ug Inhaled

Indications